Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment

Swamy Yeleswaram; Paul Smith; Timothy Burn; Maryanne Covington; Ashish Juvekar; Yanlong Li; Peg Squier; Peter Langmuir

doi:10.1016/j.clim.2020.108517

Fig. 5

Ruxolitinib dosing considerations [37]. (A) Ruxolitinib steady-state plasma concentrations (mean ± standard error) in healthy participants observed on day 10 of the multiple-dose study. (B) The pharmacokinetic–pharmacodynamic relationship established from ruxolitinib single-dose study. The solid line and dashed lines are the best-fit curve and 95% predictive interval, respectively. EC₅₀, half maximal effective concentration; q12h, every 12 h; q24h, every 24 h. From Shi JG et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 51(12);1644-54, Copyright © 2011 American College of Clinical Pharmacology, Published by John Wiley and Sons.